Form 4 for EW Edwards Lifesciences
Accepted 2026-05-08 21:16:30 ET · period of report 2026-05-07 · accession 0001225208-26-005044 · SEC index · Original document
Summary rows
Aggregated the way they appear in lists: one row per insider, transaction code and security table.
| X | Filed | Traded | Ticker | Insider | Title | Type | Price | Qty | Owned | ΔOwn | Value |
|---|---|---|---|---|---|---|---|---|---|---|---|
| DM | 2026-05-08 21:16 | 2026-05-07 | EW | Dahl Andrew M. | SVP, Corp. Ctrl | A - Grant | $0.00 | +7,005 | 16.2K | +76% | $0 |
| D | 2026-05-08 21:16 | 2026-05-08 | EW | Dahl Andrew M. | SVP, Corp. Ctrl | F - Tax | $82.76 | -289 | 15.9K | -2% | -$23.9K |
| D | 2026-05-08 21:16 | 2026-05-07 | EW | Dahl Andrew M. | SVP, Corp. Ctrl | A - Grant | $0.00 | +6,745 | 6,745 | New | $0 |
Purchase Sale Sale after option exercise All abbreviations
Every reported transaction
| # | Table | Security | Date | Code | A/D | Shares | Price | Owned after | Own | Exercise / expiry | Underlying | Footnotes |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | Common | Common Stock | 2026-05-07 | A | A | 3,985 | $0.00 | 13,170.62 | D | — | — | (F1) These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 2 | Common | Common Stock | 2026-05-07 | A | A | 3,020 | $0.00 | 16,190.62 | D | — | — | (F1) These restricted stock units were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |
| 3 | Common | Common Stock | 2026-05-08 | F | D | 289 | $82.76 | 15,901.62 | D | — | — | |
| 4 | Derivative | Employee Stock Option (Right to Acquire) | 2026-05-07 | A | A | 6,745 | $0.00 | 6,745 | D | $82.76 · 2027-05-07 to 2033-05-06 | 6,745 Common Stock | (F2) These options were granted on May 7, 2026 under the Edwards Lifesciences Corporation Long-Term Stock Incentive Compensation Program and are scheduled to become vested and exercisable commencing one year after the grant date in four equal annual installments. |